Shots:

• The approval is based on the P-III study that involves assessing Taltz (20mg for <25kg/40mg for 25-50kg/80 mg for >50 kg @12wks.- with 40/80/160mg starting doses- respectively) vs PBO in 171 patients aged 6-<18 yrs. with mod. to sev. PsO
• Results: @ 12wks.- patients achieving PASI 75 (89% vs 25%); patients achieving sPGA 0-1 (81% vs 11%); safety profile in pediatric patients is consistent with adult patients
• Taltz is a mAb targeting IL-17A cytokine. The approval marks the 5th indication for the therapy in Canada and has received its first approval in 2016 for mod. to sev. PsO- then for PsA in 2018- AS & nr-axSpA in 2020

  Ref: Lilly | Image: Fortune